Bird & Bird has advised European private equity firm Vitruvian Partners on its investment in AI-powered healthcare platform ADA Health as part of its ongoing relationship with the equity firm.
This series B financing round, with a value of $90 Million USD, was led by Leaps by Bayer, the impact investment unit of Bayer AG. In addition to Vitruvian Partners, other investors include Samsung Catalyst Fund, Inteligo Bank, F4 and Mutschler Ventures.
ADA Health combines medical knowledge with powerful artificial intelligence to create new opportunities for personalised healthcare. The goal of the financing is to further advance ADA's proven health analytics technologies and accelerate the company's path to becoming the global leader in personalised digital health. This will also strengthen the company's leading position in the US.
ADA's key technology is also available in a package of AI-powered business solutions. The company partners with several of the world's leading healthcare systems, health insurers, life science companies and global non-profit organisations. The goal of these collaborations is to integrate symptom analysis and signposting solutions into digital health offerings to enable better outcomes for patients, consumers, and healthcare providers.
Vitruvian Partners was advised by the following Bird & Bird lawyers: Partner Dr. Hans Peter Leube, LL.M., (lead), Counsel Marianne Nawroth and Associate Tamara Böhmert (all Corporate/M&A, Frankfurt).
